# Axcynsis Therapeutics

Source: https://onco.cc/companies/axcynsis-therapeutics/  
OnCo record `axcynsis-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Axcynsis Therapeutics makes antibody-drug conjugates, antibodies that carry a cell-killing drug to cancer cells; its first one, aimed at the protein CLDN6, is in an early trial in advanced solid tumours.

## Summary

Axcynsis Therapeutics Pte Ltd is a Singapore antibody-drug conjugate company with a Shanghai office. It was established in March 2022 as Tetris Therapeutics, according to the company, and later renamed. Its platform includes the AxcynDOT payload technology. AT03-65, a CLDN6-targeting ADC and the first programme on AxcynDOT, received FDA IND clearance in January 2025 and began a first-in-human phase 1 trial in the United States in advanced CLDN6-positive solid tumours, announced in February 2026 (NCT06809114). Preclinical programmes include a DLL3 by SEZ6 bispecific ADC for small cell lung cancer, a dual-payload ROR1 ADC, a HER2 ADC and an ALPP/ALPPL2 ADC. In May 2022, as Tetris Therapeutics, it raised USD 15 million in seed funding. Its first registered cancer trial, NCT06809114, was posted on ClinicalTrials.gov in February 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Axcynsis Therapeutics Pte Ltd; Tetris Therapeutics
- HQ: Singapore
- Type: biotech
- Website: https://axcynsis.com/

## Notes

- Founding date and seed round from the company's May 2022 release; pipeline and phase 1 start from the company's pipeline page and February 2026 release, read on 29 October 2026.

## Sources

- Official website: https://axcynsis.com/
- Pipeline: https://axcynsis.com/pipeline/
- Phase 1 start release, February 2026: https://axcynsis.com/phase-1-clinical-trial/
- ClinicalTrials.gov: phase 1 trial of AT03-65 (NCT06809114): https://clinicaltrials.gov/study/NCT06809114

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Bispecific ADC](https://onco.cc/technologies/bispecific-adc/), [Dual-payload ADC](https://onco.cc/technologies/dual-payload-adc/)
- targets: [Claudin 6](https://onco.cc/targets/cldn6/), [DLL3](https://onco.cc/targets/dll3/), [HER2](https://onco.cc/targets/her2/), [ROR1](https://onco.cc/targets/ror1/)

---
JSON: https://onco.cc/api/v1/entities/axcynsis-therapeutics.json